Procoagulant expression in platelets and defects leading to clinical disorders.
about
Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristicsThrombus formation without platelets under inflammatory condition: an in vitro study.Inherited platelet-based bleeding disorders.Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.The role of calpain-myosin 9-Rab7b pathway in mediating the expression of Toll-like receptor 4 in platelets: a novel mechanism involved in α-granules trafficking.Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges.Platelet senescence and phosphatidylserine exposure.Inherited defects in platelet signaling mechanisms.Historical perspective and future directions in platelet research.Role of monocytes in atherogenesis.Procoagulant potential of platelet alpha granules.Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment.Characterizing blood microparticles: technical aspects and challenges.Lactadherin and clearance of platelet-derived microvesiclesKinetic regulation of the binding of prothrombin to phospholipid membranes.Factor XA binding to phosphatidylserine-containing membranes produces an inactive membrane-bound dimer.Molecular imaging of platelet activation in thrombus.Activated platelets and atherosclerosis.Transfusion-related acute lung injury: transfusion, platelets and biological response modifiers.Role of CD73 and extracellular adenosine in disease : Presented by Maria P. Abbracchio.Platelet binding and phagocytosis by macrophages.Protein kinase Ctheta negatively regulates store-independent Ca2+ entry and phosphatidylserine exposure downstream of glycoprotein VI in platelets.Platelet characteristics change with aging: role of estrogen receptor beta.Apoptotic activity in stored human platelets.Studies of biological functions in blood cells from individuals with large platelets.Phospholipid content, expression and support of thrombin generation of neonatal platelets.Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.Effects of platelets and platelet-derived material on the activated partial thromboplastin time (Cephotest) coagulation test.Platelet-derived microvesicles transfer tissue factor to monocytes but not to neutrophils.Microparticles shed from different antigen-presenting cells display an individual pattern of surface molecules and a distinct potential of allogeneic T-cell activation.Thrombin generation in vascular tissue.Two subpopulations of thrombin-activated platelets differ in their binding of the components of the intrinsic factor X-activating complex.Silver nanoparticles enhance thrombus formation through increased platelet aggregation and procoagulant activity
P2860
Q28167653-2C0A773F-E01B-43C4-9A25-C001BD71E14CQ33279035-E8B4AA37-B1C6-4CF2-B8A2-9DAC394E04E8Q33349071-7CECA10B-2AE1-49B2-B092-86A127D71B14Q33382014-27904F03-DB34-4316-9AE3-BC59FE3E01BDQ33413094-A602FA65-6C19-4EAD-8010-B81C13E6E5B1Q33615785-EF9273FB-F2AE-4AD2-A44B-4A68D2DB4BBEQ34065484-97BD8768-BA69-4FDD-A68F-09C7D00392E3Q35181715-6912C579-B400-47BA-9EB8-A2C0BC527C68Q35185593-83181F5C-08A1-4797-91C8-23A4A5346547Q35541858-00729E0E-99B7-4BC0-901D-90DD7C89DEEDQ36060826-A0EFC3B4-D07F-41AD-8560-D9042EBC1459Q36473090-33E121DD-896B-4024-9E2F-68492B654F6BQ37004064-9F3866F0-0FB2-4EFE-AA94-5885103C9782Q37086945-0501F005-4BA0-4F7E-AB13-2E06431D2DBCQ37166399-964EE18F-2445-4B1D-B4D4-4730712B543FQ37392559-E1CA6396-D092-4E88-BDE6-BEBE4C02FEB4Q37395376-AB188CF2-3634-4D62-AF74-286AB0A753DDQ37786647-F3451213-2CE7-414C-873D-4F2E6E32FECDQ38725992-6DA0D159-AF6D-4CF0-889C-4EE26C1ED977Q39393094-FB02E420-0FE7-4348-B570-53F1EE561471Q40239468-87950BCF-602B-41E2-8787-DB517CE1C168Q41191812-A9811834-2D64-4B0B-B943-2EBFDF444D44Q42482148-674E517A-955A-4E13-AF71-8915BF75811DQ44380505-EC134D5C-AB27-41C5-92FD-B51B4FEC1068Q44720854-FFEBEB5C-C3B8-4B14-9476-9923D4FE5974Q46270830-A2A0111F-C3EB-4483-B8DE-704633D96DFDQ46432730-09E55395-0D6A-44A0-B311-E8E0E8702A08Q46632069-37D05FC5-5953-4C76-8B3E-A4189D67622EQ47576372-EBBE291A-4BF2-43C3-A6E6-8321CCE73265Q50771153-385BDECF-7EFD-42CF-BB48-84C48EC82804Q53640998-839A67A8-D43B-4B9F-87CB-C9615B63C41BQ54293957-32E2882C-66F5-43A9-A2B2-9D65E3FBD6F6Q58390475-B4A61104-3AFE-4A01-B0F8-EB34F24860C2
P2860
Procoagulant expression in platelets and defects leading to clinical disorders.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Procoagulant expression in platelets and defects leading to clinical disorders.
@ast
Procoagulant expression in platelets and defects leading to clinical disorders.
@en
Procoagulant expression in platelets and defects leading to clinical disorders.
@nl
type
label
Procoagulant expression in platelets and defects leading to clinical disorders.
@ast
Procoagulant expression in platelets and defects leading to clinical disorders.
@en
Procoagulant expression in platelets and defects leading to clinical disorders.
@nl
prefLabel
Procoagulant expression in platelets and defects leading to clinical disorders.
@ast
Procoagulant expression in platelets and defects leading to clinical disorders.
@en
Procoagulant expression in platelets and defects leading to clinical disorders.
@nl
P1476
Procoagulant expression in platelets and defects leading to clinical disorders.
@en
P2093
P304
P356
10.1161/01.ATV.19.12.2841
P407
P577
1999-12-01T00:00:00Z